MAIA Biotechnology Files 2024 10-K Amidst Offerings
Ticker: MAIA · Form: 10-K · Filed: Mar 21, 2025 · CIK: 1878313
Sentiment: neutral
Topics: 10-K, financing, pharmaceuticals
TL;DR
MAIA Bio's 2024 10-K is out, showing lots of private placements and registered direct offerings. Keep an eye on cash burn.
AI Summary
MAIA Biotechnology, Inc. filed its 2024 10-K on March 21, 2025, detailing its operations and financial status for the fiscal year ending December 31, 2024. The company, incorporated in Delaware and based in Chicago, IL, operates in the Pharmaceutical Preparations sector. The filing indicates various private placement and registered direct offerings throughout 2023 and 2024, involving entities and individuals such as Louie NgarYee, Steven Chaouki, Cristian Luput, and FGMKLLC.
Why It Matters
This 10-K filing provides a comprehensive overview of MAIA Biotechnology's financial health and strategic activities, including capital raises, which are crucial for investors to assess the company's future prospects and operational stability.
Risk Assessment
Risk Level: medium — The company's engagement in multiple private placements and registered direct offerings suggests a need for capital, which can indicate potential financial pressures or dilution risks for existing shareholders.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for the 10-K)
- 2025-03-21 — Filing Date (Date the 10-K was submitted to the SEC)
Key Players & Entities
- MAIA Biotechnology, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-21 (date) — Filing date
- Chicago, IL (location) — Company business address
- Louie NgarYee (person) — Involved in private placement
- Steven Chaouki (person) — Involved in private placement
- Cristian Luput (person) — Involved in private placement
- FGMKLLC (company) — Involved in private placement
FAQ
What were the total proceeds raised from the various private placement and registered direct offerings mentioned in the filing for the fiscal year 2024?
The filing mentions several private placement and registered direct offerings throughout 2024, but specific total dollar amounts raised are not detailed in the provided header information.
What is the primary business of MAIA Biotechnology, Inc. as described in the 10-K?
MAIA Biotechnology, Inc. operates in the Pharmaceutical Preparations sector, as indicated by its Standard Industrial Classification code [2834].
When was MAIA Biotechnology, Inc. incorporated and where is its principal place of business?
The company was incorporated in Delaware (DE) and its business address is located at 444 West Lake Street, Suite 1700, Chicago, IL 60606.
Are there any specific named individuals or entities highlighted as significant participants in the company's financing activities during 2024?
Yes, the filing references Louie NgarYee, Steven Chaouki, Cristian Luput, and FGMKLLC in the context of private placements during 2024.
What is the SEC file number for MAIA Biotechnology, Inc.'s 10-K filing?
The SEC file number for this 10-K filing is 001-41455.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 21, 2025 by Louie NgarYee regarding MAIA Biotechnology, Inc. (MAIA).